Current Issue : Journal of Clinical Psychopharmacology

Secondary Logo

Journal Logo

January/February 2023 - Volume 43 - Issue 1
pp: 1-85



Real-World Clinical Practice Among Patients With Bipolar Disorder and Chronic Kidney Disease on Long-term Lithium Therapy

Kumar, Rakesh; Joseph, Boney; Pazdernik, Vanessa M.; More

Journal of Clinical Psychopharmacology. 43(1):6-11, January/February 2023.

Reproductive Safety of Trazodone After Maternal Exposure in Early Pregnancy: A Comparative ENTIS Cohort Study

Dao, Kim; Shechtman, Svetlana; Diav-Citrin, Orna; More

Journal of Clinical Psychopharmacology. 43(1):12-19, January/February 2023.

Two-Injection Start Regimen of Long-Acting Aripiprazole in 133 Patients With Schizophrenia

Cuomo, Alessandro; Aguglia, Eugenio; Biagini, Stefano; More

Journal of Clinical Psychopharmacology. 43(1):35-38, January/February 2023.

α-Lipoic Acid as Adjunctive Treatment for Schizophrenia: A Randomized Double-Blind Study

De Lima, David Nunes Jr; Costa Filho, Carlos Winston Luz; Frota, Ilgner Justa; More

Journal of Clinical Psychopharmacology. 43(1):39-45, January/February 2023.





Duration: 5:25

In a commentary published in the Journal of Clinical Psychopharmacology, Dr. Rishab Gupta (Brigham and Women's Hospital/Harvard Medical School) and Dr. Swarndeep Singh (Government Medical College and Hospital, Chandigarh, India) cast a critical eye on India’s regulatory approval for the use of endoxifen for the treatment of manic episodes in patients with bipolar disorder type 1. In their article and in this podcast, they suggest that there are important deficiencies in the research that was used to support the regulatory approval. No other country has approved endoxifen for treating bipolar disorder. They caution that endoxifen should be considered as an option to treat acute mania only after a careful consideration of risks/benefits with the patient and their family and after providing them with a list of alternative medications.

Duration: 8:01

Lithium is considered a standard treatment for bipolar disorder, but it remains underprescribed, in part because of its association with kidney dysfunction.
In this podcast, Dr. Balwinder Singh discusses an article he and his colleagues published in the January-February 2023 issue of the Journal of Clinical Psychopharmacology on “real-world” clinical practice involving patients with bipolar disorder (BD) and chronic kidney disease (CKD). In their study, patients with BD and CKD who discontinued lithium use after CKD diagnosis had a higher risk for a relapse of their mood disorder as well as a shorter time to the first mood episode, suggesting a need for more thorough discussion before discontinuing lithium after a diagnosis of CKD.

Show: